UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

FORM 8-K

 $\label{eq:CURRENT REPORT} CURRENT REPORT \\ \mbox{Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934} \\$

Date of Report (Date of earliest event reported) February 24, 2009

.....

HENRY SCHEIN, INC.

(Exact name of registrant as specified in its charter)

DELAWARE	0-27078	11-3136595			
(State or other jurisdiction of incorporation)	(Commission File Number)	(IRS Employer Identification No.)			

 135 DURYEA ROAD, MELVILLE, NEW YORK
 11747

 (Address of principal executive offices)
 (Zip Code)

Registrant's telephone number, including area code (631) 843-5500

NOT APPLICABLE

(Former name or former address, if changed since last report.)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

[] Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

[] Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

[] Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

[] Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Item 2.02. Results of Operations and Financial Condition.

On February 24, 2009, Henry Schein, Inc. issued a press release reporting the financial results for the three months and full year ended December 27, 2008. The full text of the press release is attached hereto as Exhibit 99.1 and is incorporated herein by reference.

Item 9.01. Financial Statements and Exhibits.

- (a) Not applicable.
- (b) Not applicable.
- (c) Not applicable.
- (d) Exhibit 99.1 Press Release dated February 24, 2009.

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

HENRY SCHEIN, INC.

By: /s/ Steven Paladino Steven Paladino Executive Vice President and Chief Financial Officer (principal financial and accounting officer) EXHIBIT INDEX

Exhibit No. Description

99.1 Press Release dated February 24, 2009.

FOR IMMEDIATE RELEASE

HENRY SCHEIN REPORTS FOURTH QUARTER RESULTS EPS from continuing operations increases 8% to \$0.90, excluding restructuring costs Company revises 2009 guidance

MELVILLE, N.Y. (February 24, 2009) - Henry Schein, Inc. (NASDAQ: HSIC), the largest provider of healthcare products and services to office-based practitioners in the combined North American and European markets, today reported financial results for the quarter and year ended December 27, 2008.

Net sales for the fourth quarter of 2008 were \$1.6 billion, a decrease of 7.5% compared with the fourth quarter of 2007. This consists of a 1.8% decline in local currencies (3.0% decline in internal net sales and 1.2% growth from acquisitions) and a 5.7% decline related to foreign currency exchange (see Exhibit A for details of sales growth). The Company previously announced an initiative of reducing sales of certain lower-margin pharmaceutical products. Excluding sales of those products, internal net sales in local currencies declined 1.1%.

Income from continuing operations for the fourth quarter of 2008 was \$64.2 million, or \$0.72 per diluted share. These results include certain restructuring costs (discussed below) of \$23.2 million (or \$0.18 per diluted share, after-tax) related to the elimination of approximately 300 positions from operations and the closing of several smaller facilities. Excluding the impact of these restructuring costs, income from continuing operations for the quarter was \$80.2 million, or \$0.90 per diluted share, an increase of 4.5% and 8.4%, respectively, compared with the fourth quarter of 2007 (see Exhibit B for reconciliation of GAAP net income and EPS to non-GAAP adjusted net income and EPS). The Company recorded a loss on discontinued operations during the fourth quarter of 2008 of \$7.3 million (or \$0.08 per diluted share, after-tax) related to the previously announced decision to exit its wholesale ultrasound business.

"Although internal net sales declined slightly during the fourth quarter, we are pleased to report that excluding restructuring costs, we had solid operating margin expansion and 8% growth in diluted EPS from continuing operations," said Stanley M. Bergman, Chairman and Chief Executive Officer of Henry Schein. "Operating margin for the quarter, excluding restructuring charges, reached 8.1%, which is up 76 basis points compared with the prior year fourth quarter.

> 1 -more-

For the year our operating margin, excluding restructuring charges, was 6.9%, which is up 35 basis points and is in line with our stated Company goal for annual operating margin expansion."

Dental Group sales of \$665 million declined 2.4%, consisting of a 0.3% decline in local currencies (all internal) and a 2.1% decline related to foreign currency exchange. The 0.3% internal decline in local currencies consists of a Dental consumable merchandise sales increase of 1.4% and a Dental equipment sales and service revenues decline of 3.6%.

"Our fourth quarter Dental Group results reflect the current economic environment and uncertainty, particularly impacting overall demand for dental equipment," commented Mr. Bergman.

Medical Group sales of \$349 million declined 12.6%, consisting of a 13.5% decline in internally generated sales and 0.9% growth due to acquisitions. Excluding sales of certain lower-margin pharmaceutical products, noted above, internal Medical Group sales declined approximately 6% and declined approximately 1% when also excluding sales of influenza vaccine. Fourth quarter Medical Group sales growth was negatively impacted by the timing of influenza vaccine sales compared to prior year.

"During the fourth quarter we sold 3.1 million doses of influenza vaccine. For the year we sold 13.6 million doses, which is at the midpoint of our guidance range," said Mr. Bergman. "We are also pleased with the results from our animal health business. Sales to our veterinary customers represented about 14% of the Medical Group's fourth quarter total sales and were up approximately 4.3%."

For the quarter, International Group sales of \$528 million declined 10.8%, consisting of 2.9% growth in local currencies (0.1% internally generated and 2.8% from acquisitions) and a 13.7% decline related to foreign currency exchange.

"Results in our International Group reflect a strengthening of the U.S. dollar," added Mr. Bergman. "Yet we are pleased to report solid internal sales growth in most of our major markets, with double-digit internal sales gains in local currencies reported in Australia and New Zealand."

Technology and Value-Added Services Group sales of \$42 million increased 6.5% during the quarter, consisting of 10.9% growth in local currencies (all internally generated) and a 4.4% decline related to foreign currency exchange.

"During the quarter we saw continued strong growth in financial services as equipment and practice financing transactions posted 10.4% growth, which follows 30% growth reported in the previous quarter. Our electronic services business also was strong during the quarter," stated Mr. Bergman. 2 -more-

Full Year Results

For the 2008 full year, net sales of \$6.4 billion represent an increase of 8.3% compared with 2007. This increase consists of 7.5% local currency growth (1.3% internally generated and 6.2% from acquisitions) and 0.8% related to foreign currency exchange. Excluding sales of certain lower-margin pharmaceutical products, noted above, internal net sales growth in local currencies was 3.6%.

Income from continuing operations for 2008 was \$251.0 million, or \$2.75 per diluted share. Excluding the charge in the third quarter of 2008 related to the Lehman Brothers bankruptcy (\$0.03 per diluted share, after-tax) and the fourth quarter restructuring costs, income from continuing operations for 2008 was \$270.0 million, or \$2.96 per diluted share, reflecting growth of 14.4% and 14.3%, respectively, compared with 2007.

Stock Repurchase Plan

Henry Schein repurchased 568,410 shares of common stock during the fourth quarter of 2008 for a total purchase price of approximately \$28 million. The impact of this share repurchase was immaterial to fourth quarter diluted EPS. During 2008 the Company repurchased 1,621,710 shares of common stock for a total purchase price of approximately \$88 million. Approximately \$58 million remains authorized for future common stock repurchases.

Restructuring Costs

In November 2008 Henry Schein announced plans to eliminate approximately 300 positions from its operations around the world and to close several smaller facilities. This initiative is substantially complete. The Company recorded costs associated with this initiative of \$23.2 million in the fourth quarter of 2008, and expects to record remaining costs of \$1 million to \$3 million in the first quarter of 2009. Annual pretax cost savings from this initiative are expected to be approximately \$24 million to \$27 million and are included in our 2009 EPS guidance.

2009 EPS Guidance

"We are revising our full-year 2009 financial guidance due to worsening economic conditions, our expectation for continued economic weakness and the strengthening of the U.S. dollar," commented Mr. Bergman. Henry Schein's 2009 financial guidance now is as follows:

o 2009 diluted EPS is expected to be \$3.11 to \$3.26, representing growth of 5% to 10% compared with reported 2008 results, excluding charges related to the Lehman Brothers

bankruptcy, as well as restructuring costs. This compares with previous guidance for 2009 diluted EPS of \$3.27 to \$3.36. The 2009 guidance does not include any restructuring costs expected to be recorded during the year.

- o For the first quarter of 2009, the Company expects diluted EPS to be in the range of flat to growth in the low-single-digit percentages, compared with the first quarter of 2008, excluding restructuring costs expected to be recorded during the quarter, as described above.
- o 2009 diluted EPS guidance is for current continuing operations including completed or previously announced acquisitions, and does not include the impact of potential future acquisitions, if any.

Fourth Quarter Conference Call Webcast

The Company will hold a conference call to discuss fourth quarter financial results today, beginning at 10:00 a.m. Eastern Standard Time. Individual investors are invited to listen to the conference call over the Internet through Henry Schein's Web site at www.henryschein.com. In addition, a replay will be available beginning shortly after the call has ended.

About Henry Schein

Henry Schein, a Fortune 500(R) company and a member of the NASDAQ 100(R) Index, is recognized for its excellent customer service and highly competitive prices. The Company's four business groups - Dental, Medical, International and Technology - serve more than 575,000 customers worldwide, including dental practitioners and laboratories, physician practices and animal health clinics, as well as government and other institutions.

The Company operates through a centralized and automated distribution network, which provides customers in more than 200 countries with a comprehensive selection of more than 90,000 national and Henry Schein privatebrand products in stock, as well as more than 100,000 additional products available as special-order items.

Henry Schein also offers a wide range of innovative value-added practice solutions for healthcare professionals, such as ArubA(R), the Company's electronic catalog and ordering system. Its leading practice-management software solutions have an active user base of more than 60,000 practices, including DENTRIX(R), Easy Dental(R), Oasis(R) and EXACT(R) for dental practices, MicroMD(R) for physician practices, and AVImark(R) for animal health clinics.

Headquartered in Melville, N.Y., Henry Schein employs over 12,500 people and has operations or affiliates in 23 countries. The Company's net sales reached a record \$6.4 billion in 2008. For more information, visit the Henry Schein Web site at www.henryschein.com.

In accordance with the "Safe Harbor" provisions of the Private Securities Litigation Reform Act of 1995, we provide the following cautionary remarks regarding important factors that, among others, could cause future results to differ materially from the forward-looking statements, expectations and assumptions expressed or implied herein. All forward-looking statements made by us are subject to risks and uncertainties and are not guarantees of future performance. These forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause our actual results, performance and achievements or industry results to be materially different from any future results, performance or achievements are identified by the use of such terms as "may," "could," "expect," "intend," "believe," "plan," "estimate," "forecast," "project," "anticipate" or other comparable terms. A full discussion of our operations and financial condition, including factors that may affect our business and future prospects, is contained in documents we have filed with the SEC and will be contained in all subsequent periodic filings we make with the SEC. These documents identify in detail important risk factors that could cause our actual performance to differ materially from current expectations.

Risk factors and uncertainties that could cause actual results to differ materially from current and historical results include, but are not limited to: decreased customer demand and changes in vendor credit terms; disruptions in financial markets; general economic conditions; competitive factors; changes in the healthcare industry; changes in regulatory requirements that affect us; risks associated with our international operations; fluctuations in quarterly earnings; our dependence on third parties for the manufacture and supply of our products; transitional challenges associated with acquisitions, including the failure to achieve anticipated synergies; financial risks associated with acquisitions; regulatory and litigation risks; the dependence on our continued product development, technical support and successful marketing in the technology segment; our dependence upon sales personnel and key customers; our dependence on our senior management; possible increases in the cost of shipping our products or other service issues with our third-party shippers; risks from rapid technological change; risks from potential increases in variable interest rates; possible volatility of the market price of our common stock; certain provisions in our governing documents that may discourage third-party acquisitions of us; and changes in tax legislation that affect us. The order which these factors appear should not be construed to indicate their relative The order in importance or priority.

We caution that these factors may not be exhaustive and that many of these factors are beyond our ability to control or predict. Accordingly, any forwardlooking statements contained herein should not be relied upon as a prediction of actual results. We undertake no duty and have no obligation to update forwardlooking statements.

> (TABLES TO FOLLOW) 5 - more -

HENRY SCHEIN, INC. CONSOLIDATED STATEMENTS OF INCOME (in thousands, except per share data)

		Three Months Ended		Years Ended				
		December 27, [2008		cember 29, 2007		cember 27, 2008	Deo	cember 29, 2007
		unaudited)		unaudited)				
Net sales Cost of sales		1,584,653 1,116,987		1,712,836 1,229,143		6,394,874 4,510,336		5,904,416 4,187,842
Gross profit		467,666		483,693		1,884,538		1,716,574
Operating expenses: Selling, general and administrative Restructuring costs		339,580 23,240		358,251 		1,441,695 23,240		1,328,635
Operating incomeOther income (expense):		104,846		125,442		419,603		387,939
Interest income Interest expense Other, net		4,138 (6,464) (239)		3,765 (6,685) 288		16,355 (29,439) (5,704)		16,531 (24,836) 4,630
Income from continuing operations before taxes, minority interest and equity in earnings (losses) of affiliates Income taxes Minority interest in net income of subsidiaries Equity in earnings (losses) of affiliates		102,281 (32,832) (6,258) 1,017		122,810 (40,237) (6,438) 614		400,815 (132,924) (21,917) 5,037		384,264 (130,603) (17,442) (73)
Income from continuing operations				76,749		 251,011		236,146
Discontinued operations: Income (loss) from operations of discontinued components (including write-down of long- lived assets of \$8.5 million in 2008 and a write-down of long-lived assets of \$32.7 million and a net gain on sale of discontinued operations of \$1.1 million in 2007) Income tax benefit (expense)		<u>ົ 3</u> ໌ 880 ໌		2,315 (795)		(12,146) 4,278		(33,441) 12,468
Income (loss) from discontinued operations		(7,297)		1,520		(7,868)		(20,973)
Net income	\$	56,911	\$	78,269	\$	243,143	\$	215,173
Earnings from continuing operations per share: Basic		0.72	\$	0.86	\$	2.82	\$	2.67
Diluted	\$	0.72	\$	0.83	\$	2.75	\$	2.59
Income (loss) from discontinued operations per share: Basic	\$	(0.08)	\$	0.02	\$	(0.09)	\$	(0.24)
Diluted	\$	============ (0.08) =========	\$	======= 0.02 =======	\$	(0.08)	\$	(0.23)
Earnings per share: Basic	\$	0.64	\$	0.88	\$	2.73	\$	2.43
Diluted	\$	0.64	\$	0.85 	\$	2.67	\$	2.36
Weighted-average common shares outstanding: Basic		88,673		89,082		89,080		88,559
Diluted		======================================		====== 92,031		====== 91,221		====== 91,163
	==		==:		===		==:	=======

Note: The above prior period amounts have been adjusted to reflect the effects of our discontinued operations.

HENRY SCHEIN, INC. CONSOLIDATED BALANCE SHEETS (in thousands, except share and per share data)

	cember 27, 2008	Deo	cember 29, 2007
ASSETS Current assets:			
Cash and cash equivalents Available-for-sale securities Accounts receivable, net of reserves of \$42,855 and \$41,315 Inventories, net Deferred income taxes Prepaid expenses and other	\$ 369,570 734,027 731,654 36,974 194,047	\$	247,590 997 708,307 666,786 32,827 192,292
Total current assets Property and equipment, net Goodwill Other intangibles, net Investments and other	2,066,272 247,835 922,952 214,093 148,482		1,848,799 247,671 917,194 192,420 107,900
Total assets	\$ 3,599,634	\$	3,313,984
LIABILITIES AND STOCKHOLDERS' EQUITY Current liabilities: Accounts payable	\$ 554,773 4,936 156,405 135,523 69,792 262,236 1,183,665 266,646 91,249 58,109 67,780	\$	474,009 8,977 24,319 136,291 73,278 223,765 940,639 423,274 80,260 53,906 35,923
<pre>Stockholders' equity: Preferred stock, \$.01 par value, 1,000,000 shares authorized, none outstanding Common stock, \$.01 par value, 240,000,000 shares authorized, 89,351,849 outstanding on December 27, 2008 and 89,603,660 outstanding on December 29, 2007 Additional paid-in capital Retained earnings Accumulated other comprehensive income Total stockholders' equity</pre>	894 705,799 1,195,771 29,721 1,932,185		896 673,763 1,005,055 100,268 1,779,982
Total liabilities and stockholders' equity	\$ 3,599,634	\$	3,313,984

HENRY SCHEIN, INC. CONSOLIDATED STATEMENTS OF CASH FLOWS (in thousands)

Impairment from write-down of long-lived assets of discontinued operations8,484 8,484Depreciation and amortization18,94428,915Stock-based compensation expense2,3695,833Provision for losses on trade and other accounts receivable2,544322Provision for losses on trade and other accounts receivable2,744322Provision for losses on trade and other accounts receivable2,744322Provision for (benefit from) deferred income taxes(2,792)9,326Stock issued to 401(k) planUndistributed (earnings) losses of affiliates(1,017)(614Minority interest in net income of subsidiaries6,2586,438Other			Three Mor		
Cash flows from operating activities: Net income Adjustments to reconcile net income to net cash provided by contrained activities: Impairment from write-down of long-lived assets of discontinued operations g, 944 Cash flows from for a species on trade and other accounts receivable 2, 544 322 Provision for losses on trade and other accounts receivable 2, 544 322 Provision for losses on trade and other accounts receivable 2, 544 322 Provision for losses on trade and other accounts receivable 2, 544 322 Provision for losses on trade and other accounts receivable 2, 544 322 Changes in operating assets and liabilities, net of acquisitions: 4, 628 4, 647 1, 5171 (Gata) Changes in operating assets and liabilities, net of acquisitions: 39, 917 66, 565 129, 595 Other current assets 14, 710 (44, 633 Accounts payable and acrued expenses 47, 7653 (23, 168; Accounts payable and acrued expenses 120, 765 120, 765 120, 765 120, 765 120, 764 121, 751 (22, 772) (22, 781 (23, 782 Parchases of available-for-sale securities<		Deceml 20	ber 27, 008	Dec	ember 29, 2007
Net income\$ 56,911\$ 78,269Adjustments to reconcile net income to net cash provided by operating activities: Gain on sale of discontinued operation, net of tax					
Adjustments to reconcile net income to net cash provided by operating activities: Gain on sale of discontinued operation, net of tax	Cash flows from operating activities:				
Gain on sale of discontinued operation, net of tax(1,602)Impairment from write-down of long-lived assets of8,484Observation and amorization8,484Depreciation and amorization2,3695,833Provision for losses on trade and other accounts receivable2,544322Provision for (benefit from) deferred income taxes(2,722)9,326Undistributed (earnings) losses of affiliates(1,617)(644Minority interest in net income of subsidiaries6,2586,438OtherAccounts receivable39,91766,557Investing assets and liabilities, net of acquisitions:Accounts payable and accrued expensesAccounts payable and accrued expensesPurchases of fixed assetsPurchases of fixed assetsPurchases of asset for mousiness divestituresPurchases of available-for-sale securitiesPurchases of available-for-sale securitiesProceeds from financing activities:Proceeds from financing activitiesProceeds from finan	Adjustments to reconcile net income to net cash	\$	56,911	\$	78,269
Depreciation and amortization18,94420,915Stock-based compensation expense2,3695,833Provision for losses on trade and other accounts receivable2,544322Provision for (benefit from) deferred income taxes(2,792)9,326Stock issued to 401(k) plan(1,017)(614Minority interest in net income of subsidiaries(2,782)(3,642)Changes in operating assets and liabilities, net of acquisitions:39,91760,557Accounts receivable(1,78)15,995Other(1,78)15,995Accounts payable and accrued expenses(1,78)120,286Cash provided by operating activities196,085120,286Paynents for equity investment and business acquisitions, net of faxed assets divestitures(12,751)(23,798)Purchases of fixed assets(12,751)(23,798)Proceeds from business divestitures	Gain on sale of discontinued operation, net of tax				(1,602)
Stock-based compensation expense2,8695,833Provision for losses on trade and other accounts receivable2,644322Provision for (benefit from) deferred income taxes(2,792)9,326Stock issued to 401(k) plan					
Provision for losses on trade and other accounts receivable2,544322Provision for (benefit from) deferred income taxes(2,792)9,326Stock issued to 401(k) plan(2,792)9,326Undistributed (earnings) losses of affiliates(1,617)(614Minority interest in net income of subsidiaries2,282(3,642)Changes in operating assets and liabilities, net of acquisitions:39,91760,557Accounts receivable(1,78)15,995Other(1,78)15,995Accounts payable and accrued expenses(1,78)120,286Cash provided by operating activities196,685120,286Payments for equity investment and business acquisitions, net of fixed assets investing activities(12,751)(23,798)Payments for equity investment and business acquisitions, net of cash acquired(12,7540)(81,884Proceeds from subs of available-for-sale securities4,15927,750Net cash uses of available-for-sale securities4,15927,750Net cash use of investing activities(2,272)(82,019)Cash received from (payments for) foreign exchange forward contract settlements(2,746Other(3,377)488Proceeds from issuance of long-term debt					,
Provision for (benefit from) deferred income taxes(2, 792)9, 326Stock issued to 404(k) plan(1, 017)(614)Minority interest in net income of subsidiaries(2, 582)(3, 642)OtherChanges in operating assets and liabilities, net of acquisitions:2, 282(3, 642)Accounts receivable178)(178)15, 995Other current assets(1, 71)(48, 353)Accounts payable and accrued expenses47, 653(23, 158)Net cash provided by operating activities:196, 085(27, 792)Payments for equity investment and business acquisitions, net of cash acquired(12, 751)(23, 798)Payments for equity investment and business acquisitions, net of cash acquired(12, 751)(23, 798)Net cash used in investing activities:Proceeds from fugaments for) foreign exchange forward contract settlements(12, 751)(23, 798)OtherNet cash used in investing activities:Proceeds from investing activities:Proceeds from issuance of long-term debtProceeds from issuance of sload activitiesProceeds from issuance of sload components for change activitiesProceeds from from payments for long-term debtProceeds from issuance of sload upon excise of stock optionsProceeds from issuan					,
Stock issued to 401(k) plan					
Undistributed (earnings) losses of affiliates(1, 017)(614Minority interest in net income of subsidiaries6,2586,438Other2,282(3,642)Changes in operating assets and liabilities, net of acquisitions:39,91760,557Accounts receivable(178)15,995Other current assets(177)(48,353Accounts payable and accrued expenses47,653(22,158)Net cash provided by operating activities:196,085120,286Purchases of fixed assets(16,2540)(81,884)Cash flows from investing activities(12,751)(23,798)Payments for equity investment and business acquisitions, net of cash acquired(162,540)(81,884)Cash received from business divestitures(162,540)(81,884)Cash roceeds from (payments for) foreign exchange forward contract settlements(13,377)488Other(23,777)488(3,582)(14,11)Proceeds from issuance of long-term debt(1,411)5,766Proceeds from issuance of sock upon exercise of stock options(682,272)(82,019)Proceeds from issuance of cock upon exercise of stock options(27,843)Proceeds from issuance of cock upon exercise of stock options(26,920)3,732Net cash provided by (used in) financing activities(36,929)3,732Net cash provided by (used in) financing activities(36,929)3,732Net cash provided by (used in) financing activities(27,458)Proceeds from issuance of stock upon exe					
Minority interest in net income of subsidiaries6,2586,438OtherChanges in operating assets and liabilities, net of acquisitions: Accounts receivable39,91760,557Inventories1178)115,995Other current assets14,710(44,353)Accounts payable and accrued expenses14,710(44,353)Accounts payable and accrued expenses14,710(44,353)Accounts payable and accrued expenses196,085120,286Cash flows from investing activities196,085120,286Purchases of fixed assets(12,751)(23,798)Purchases of fixed assets(102,540)(81,884)Cash received from business divestitures-16,766Purchases of available-for-sale securities-16,766Purchases of available-for-sale securitiesProceeds from alse of available-for-sale securities32,246(15,261)Net proceeds from financing activities(2,7750)(22,750)Proceeds from financing activitiesProceeds from financing activitiesProceeds from financing activities(14,411)5,76627,760Principal payments for long-term debtProceeds from financing activities(36,922)3,732Payments for equivalents of lock upon exercise of stock options(27,843)-Proceeds from financing activities(36,920)3,732Net cash provided by (used in) financing activities(36,920)3,732 <tr< td=""><td></td><td></td><td></td><td></td><td></td></tr<>					
Other2,282(3,642)Changes in operating assets and liabilities, net of acquisitions: Accounts receivable39,91760,557Inventories(178)15,995Other current assets47,653(23,158)Net cash provided by operating activities196,085120,286Cash flows from investing activities:(12,751)(23,798)Purchases of fixed assets(12,751)(23,798)Payments for equity investment and business acquisitions, net of cash acquired(122,540)(81,884)Cash received from business divestitures10,766Purchases of fixed assets-10,766Purchases of no (payments for) foreign exchange forward contract settlements32,246(15,261)0Cash flows from financing activities32,246(15,261)00Other(3,377)408Proceeds from sisuance of long-term debtProceeds from issuance of stock upon exercise of stock options6082,7402,74014,1115,766Principal payments for long-term debtProceeds from issuance of stock upon exercise of stock options6082,7403,582(5,374)Proceeds from issuance of stock upon exercise of stock options902(411)5,766Proceeds from issuance of stock upon exercise of stock options902(412)-<					()
Accounts receivable39,91766,557Inventories(178)15,995Other current assets47,653(23,158)Net cash provided by operating activities196,085120,286Cash flows from investing activities:196,085120,286Payments for equity investment and business acquisitions, net of cash acquired(102,540)(81,884)Cash received from business divestituresPurchases of fixed assets4,15027,750Net cash received from business divestituresPurchases of available-for-sale securities4,15027,750Net proceeds from financing activities:32,246(15,261)Other(3,377)408Net cash used in investing activities:Proceeds from financing activities:Proceeds from issuance of long-term debtProceeds from issuance of long-term debtProceeds from repayments of) bank borrowings(1,411)5,766Principal payments for long-term debtProceeds from issuance of stock upon exercise of stock options6082,740Payments for repurchases of compon stock(27,843)-Payments for repurchases of compon stock(30,920)3,732Net cash provided by (used in) financing activitiesStock upon exercise of stock options6082,740Payments for repurchases of compon stockPayments for repurchases of compon stock </td <td>Other</td> <td></td> <td></td> <td></td> <td>(3,642)</td>	Other				(3,642)
Other current assets14,710(48,583)Accounts payable and accrued expenses47,653(23,158)Net cash provided by operating activities196,085120,286Cash flows from investing activities:196,085120,286Payments for equity investment and business acquisitions, net of cash acquired(12,751)(23,798)Payments for equity investment and business acquisitions, net of cash acquired(12,751)(23,798)Payments for equity investment and business acquisitions, net of cash acquired(102,540)(81,884)Cash received from business divestitures16,766Purchases of favailable-for-sale securitiesProceeds from sales of available-for-sale securities4,15027,750Net proceeds from (payments for) foreign exchange forward contract settlements32,246(15,261)Other(3,377)408Net cash used in investing activities(1,411)5,766Proceeds from issuance of long-term debtProceeds from issuance of stock upon exercise of stock options(6822,740)Payments for repurchases of common stock(27,843)-Payments for repurchases of common stock(27,843)-Payments for repurchases of common stock(36,920)3,732Net cash provided by (used in) financing activities82,89341,990Payments for repare chases of common stock(27,843)-Payments for repurchases of common stock(36,920)3,732Net cash provided by			39,917		60,557
Accounts payable and accrued expenses47,653(23,158)Net cash provided by operating activities196,085120,286Cash flows from investing activities:196,085120,286Purchases of fixed assets(12,751)(23,798)Payments for equity investment and business acquisitions, net of cash acquired(102,540)(81,884)Cash received from business divestitures10,765Purchases of available-for-sale securities4,15027,750Net proceeds from sales of available-for-sale securities32,246(15,261)Other(3,377)408Other(82,272)(82,019)Cash flows from financing activities:Proceeds from issuance of long-term debtProceeds from issuance of stock upon exercise of stock options(3,582)(5,374)Proceeds from issuance of stock upon exercise of stock options6082,740Payments for repurchases of common stock(27,843)Excess tax benefits related to stock-based compensation4061,071Other(30,920)3,732Net cash provided by (used in) financing activitiesProceeds from issuance of stock upon exercise of stock options62,89341,990Payments for repurchases of common stockProceeds from issuance of stock-based compensation4061,071OtherProceeds from issuance of stock-based compensation4061,071Other	Inventories		(178)		15,995
Net cash provided by operating activities196,085120,286Cash flows from investing activities:196,085120,286Payments for equity investment and business acquisitions, net of cash acquired(12,751)(23,798)Payments for equity investment and business acquisitions, net of cash acquired(102,540)(81,884)Cash received from business divestitures19,766Purchases of available-for-sale securities4,15027,750Net proceeds from sales of available-for-sale securities4,15027,750Net proceeds from (payments for) foreign exchange forward contract settlements32,246(15,261)Other(3,377)408Net cash used in investing activities(14,411)5,766Proceeds from issuance of long-term debtProceeds from issuance of stock upon exercise of stock options6082,740Payments for long-term debt(27,843)Excess tax benefits related to stock-based compensation4061,071OtherOtherOther(30,920)3,732Net cash provided by (used in) financing activities82,98341,990Cash and cash equivalents, end of periodStand cash equivalents, end of periodProceeds from issuance of stock-based compensationPayments for repurchases of common stockPayments for repurchases of common stock<					(48,353)
Net cash provided by operating activities196,085120,286Cash flows from investing activities:(12,751)(23,798)Payments for equity investment and business acquisitions, net of cash acquired(102,540)(81,884)Cash received from business divestitures10,766Purchases of available-for-sale securitiesProceeds from sales of available-for-sale securities4,15027,750Net proceeds from (payments for) foreign exchange forward contract settlements32,246(15,261)Other(3,377)408Net cash used in investing activities(82,272)(82,019)Cash flows from financing activities: Proceeds from issuance of long-term debtProceeds from issuance of stock upon exercise of stock options(1,411)5,766Principal payments for long-term debt(27,843)Payments for repurchases of common stock(27,843)Excess tax benefits related to stock-based compensation4061,071Other(30,920)3,732Proceds from issuance of stock upon exercise of stock options6082,740Payments for repurchases of common stockProvided by (used in) financing activities(30,920)3,732Net cash provided by (used in) financing activitiesProcess from issuance of stock upon exercise of stock options62,89341,999Effect of exchange rate changes on cash and cash equivalents28,364207,458Cash and cash equivalents <td>Accounts payable and accrued expenses</td> <td></td> <td></td> <td></td> <td>(23,158)</td>	Accounts payable and accrued expenses				(23,158)
Cash flows from investing activities: Purchases of fixed assets	Net cash provided by operating activities		196,085		
Purchases of fixed assets(12,751)(23,798)Payments for equity investment and business acquisitions, net of cash acquired(102,540)(81,884)Cash received from business divestitures-10,766Purchases of available-for-sale securities4,15027,750Net proceeds from (payments for) foreign exchange forward contract settlements32,246(15,261)Other(3,377)408Net cash used in investing activities(82,272)(82,019)Cash flows from financing activities: Proceeds from issuance of long-term debtProceeds from issuance of stock upon exercise of stock options(1,411)5,766Principal payments for long-term debt(27,843)-Payments for repurchases of common stock(27,843)-Excess tax benefits related to stock-based compensation Other4061,071Net cash and cash equivalents(30,920)3,732Cash and cash equivalents, beginning of period28,89341,999Cash and cash equivalents, beginning of period28,364207,458Cash and cash equivalents, end of period\$ 369,570\$ 247,590	Cash flows from investing activities:				
net of cash acquired(102,540)(81,884Cash received from business divestitures10,766Purchases of available-for-sale securities4,15027,750Net proceeds from (payments for) foreign exchange forward contract settlements32,246(15,261Other(3,377)408Other(82,722)(82,019)Cash flows from financing activities: Proceeds from issuance of long-term debtProceeds from issuance of stock upon exercise of stock options(1,411)5,766Principal payments for repurchases of common stock(27,743)Payments for repurchases of common stock -(30,920)3,732Net cash provided by (used in) financing activities(30,920)3,732Net cash and cash equivalents(30,920)3,732Cash and cash equivalents, beginning of period288,364207,458Cash and cash equivalents, end of period289,570247,590	Purchases of fixed assets		(12,751)		(23,798)
Cash received from business divestitures10,766Purchases of available-for-sale securitiesProceeds from sales of available-for-sale securities4,15027,750Net proceeds from (payments for) foreign exchange forward contract settlements32,246(15,261Other(3,377)408Net cash used in investing activities(82,272)(82,019)Cash flows from financing activities: Proceeds from (repayments of) bank borrowings(1,411)5,766Principal payments for long-term debt(3,582)(5,374)Proceeds from issuance of stock upon exercise of stock options6082,740Payments for repurchases of common stock(27,843)Payments for repurchases of common stock(30,920)3,732Net cash provided by (used in) financing activities(30,920)3,732Net change in cash and cash equivalents(1,687)(1,687)Cash and cash equivalents, beginning of period288,364207,458Cash and cash equivalents, end of period\$369,570\$247,590247,590333			(102.540)		(81,884)
Purchases of available-for-sale securities					
Net proceeds from (payments for) foreign exchange forward contract settlements					,
Other(3,377)408Net cash used in investing activities(82,272)(82,019)Cash flows from financing activities:(82,272)(82,019)Proceeds from issuance of long-term debtProceeds from (repayments of) bank borrowings(1,411)5,766Principal payments for long-term debt(3,582)(5,374)Proceeds from issuance of stock upon exercise of stock options6082,740Payments for repurchases of common stock(27,843)-Excess tax benefits related to stock-based compensation4061,071Other902(471)-Net cash provided by (used in) financing activities82,89341,999Effect of exchange rate changes on cash and cash equivalents(369,570)\$Cash and cash equivalents, end of period\$369,570\$Cash and cash equivalents, end of period\$247,590	Proceeds from sales of available-for-sale securities		4,150		27,750
Net cash used in investing activities(82,272)Cash flows from financing activities: Proceeds from issuance of long-term debt	contract settlements		32,246		(15,261)
Net cash used in investing activities(82,272)(82,019)Cash flows from financing activities:Proceeds from issuance of long-term debt	Other				
Cash flows from financing activities: Proceeds from issuance of long-term debt	Net cash used in investing activities		(82,272)		(82,019)
Proceeds from issuance of long-term debtImage: constraint of the system of	Cach flows from financing activities				
Proceeds from (repayments of) bank borrowings(1,411)5,766Principal payments for long-term debt(3,582)(5,374)Proceeds from issuance of stock upon exercise of stock options6082,740Payments for repurchases of common stock(27,843)Excess tax benefits related to stock-based compensation4061,071Other902(471)Net cash provided by (used in) financing activities(30,920)3,732Effect of exchange rate changes on cash and cash equivalents(1,687)(1,687)Cash and cash equivalents, beginning of period\$ 369,570\$ 247,590					
Principal payments for long-term debt(3,582)(5,374)Proceeds from issuance of stock upon exercise of stock options6082,740Payments for repurchases of common stock(27,843)Excess tax benefits related to stock-based compensation4061,071Other902(471)Net cash provided by (used in) financing activities(30,920)3,732Net change in cash and cash equivalents82,89341,999Effect of exchange rate changes on cash and cash equivalents(1,867)(1,867)Cash and cash equivalents, beginning of period\$ 369,570\$ 247,590					5 766
Proceeds from issuance of stock upon exercise of stock options6082,740Payments for repurchases of common stock(27,843)-Excess tax benefits related to stock-based compensation4061,071Other902(471)Net cash provided by (used in) financing activities(30,920)3,732Net change in cash and cash equivalents82,89341,999Effect of exchange rate changes on cash and cash equivalents(1,867)(1,867)Cash and cash equivalents, beginning of period\$ 369,570\$ 247,590					,
Payments for repurchases of common stock(27,843)Excess tax benefits related to stock-based compensation4061,071Other902(471)Net cash provided by (used in) financing activities(30,920)3,732Net change in cash and cash equivalents82,89341,999Effect of exchange rate changes on cash and cash equivalents, beginning of period(1,687)(1,867)Cash and cash equivalents, end of period\$ 369,570\$ 247,590					
Excess tax benefits related to stock-based compensation4061,071Other902(471)Net cash provided by (used in) financing activities(30,920)3,732Net change in cash and cash equivalents82,89341,999Effect of exchange rate changes on cash and cash equivalents(1,687)(1,867)Cash and cash equivalents, beginning of period288,364207,458Cash and cash equivalents, end of period\$ 369,570\$ 247,590					,
Net cash provided by (used in) financing activities(30,920)3,732Net change in cash and cash equivalents82,89341,999Effect of exchange rate changes on cash and cash equivalents(1,687)(1,867)Cash and cash equivalents, beginning of period288,364207,458Cash and cash equivalents, end of period\$ 369,570\$ 247,590					1,071
Net cash provided by (used in) financing activities(30,920)3,732Net change in cash and cash equivalents82,89341,999Effect of exchange rate changes on cash and cash equivalents(1,687)(1,867)Cash and cash equivalents, beginning of period288,364207,458Cash and cash equivalents, end of period\$ 369,570\$ 247,590	Other				(471)
Net change in cash and cash equivalents 82,893 41,999 Effect of exchange rate changes on cash and cash equivalents (1,687) (1,867) Cash and cash equivalents, beginning of period 288,364 207,458 Cash and cash equivalents, end of period \$ 369,570 \$ 247,590	Net cash provided by (used in) financing activities		(30,920)		3,732
Effect of exchange rate changes on cash and cash equivalents(1,687)(1,867)Cash and cash equivalents, beginning of period288,364207,458Cash and cash equivalents, end of period\$ 369,570\$ 247,590	Not shown in each and each an indicate				
Cash and cash equivalents, beginning of period 288,364 207,458 Cash and cash equivalents, end of period \$ 369,570 \$ 247,590					,
Cash and cash equivalents, end of period \$ 369,570 \$ 247,590					
	cash and cash equivalents, beginning of period		200,304		201,458
	Cash and cash equivalents, end of period	+			'

	Years Ended			d
	Dece	December 27, 2008		ember 29, 2007
Cash flows from operating activities:				
Net income Adjustments to reconcile net income to net cash provided by operating activities:	\$	243,143	\$	215,173
Gain on sale of discontinued operation, net of tax Impairment from write-down of long-lived assets of				(673)
discontinued operations		8,484		32,667
Depreciation and amortization		78,127		73,936
Stock-based compensation expense		25,429		22,553
Provision for losses on trade and other accounts receivable		6,255		1,384
Provision for (benefit from) deferred income taxes		(4,083)		(7,404)
Stock issued to 401(k) plan		4,662		4,104
Undistributed (earnings) losses of affiliates		(5,037)		73
Minority interest in net income of subsidiaries		21,917		17,442
OtherChanges in operating assets and liabilities, net of acquisitions:		150		(6,512)
Accounts receivable		(26,834)		(21,964)

Inventories	(68,36	0)	(15,946)
Other current assets	11,21	'	(58,194)
Accounts payable and accrued expenses	89,58		13,572
Accounts payable and accided expenses			13, 572
Net cash provided by operating activities	384,64	9	270,211
Cash flows from investing activities:			
Purchases of fixed assets	(50,87	0)	(56,821)
Payments for equity investment and business acquisitions,	(00)01	~)	(00)011)
net of cash acquired	(128,47	0)	(206,182)
Cash received from business divestitures		,	15,827
Purchases of available-for-sale securities	(35,92	5)	(115,066)
Proceeds from sales of available-for-sale securities	5,72		163,065
Net proceeds from (payments for) foreign exchange forward	5,72	2	103,005
contract settlements	41,33	6	(32,241)
Other	33		(10,629)
Utilei			(10,029)
Net cash used in investing activities	(167,87	7)	(242,047)
	(101/01	.,	(2+2,0+1)
Cash flows from financing activities:			
Proceeds from issuance of long-term debt			483
Proceeds from (repayments of) bank borrowings	(7,19	7)	1,212
			,
Principal payments for long-term debt	(33,72		(47,903)
Proceeds from issuance of stock upon exercise of stock options	25,64		35,459
Payments for repurchases of common stock	(82,78	'	(30,689)
Excess tax benefits related to stock-based compensation	11,04		12,668
Other	(95	4)	(2,350)
Net cash provided by (used in) financing activities	(87,97	0)	(31,120)
Net change in cash and cash equivalents	128,80	2	(2,956)
Effect of exchange rate changes on cash and cash equivalents	(6,82	2)	1,899
Cash and cash equivalents, beginning of period	247,59	9	248,647
Sector and each sector leader and of a solid	* * ***		
Cash and cash equivalents, end of period	\$ 369,57		5 247,590
	==========	= =	

- more -

Henry Schein, Inc. 2008 Fourth Quarter Sales Growth Rate Summary (unaudited)

Q4 2008 over Q4 2007

	Consolidated	Dental	Medical	International	Technology
Internal Sales Growth	-3.0%	-0.3%	-13.5%	0.1%	10.9%
Acquisitions	1.2%	0.0%	0.9%	2.8%	0.0%
Local Currency Sales Growth	-1.8%	-0.3%	-12.6%	2.9%	10.9%
Foreign Currency Exchange	-5.7%	-2.1%	0.0%	-13.7%	-4.4%
Total Sales Growth	-7.5%	-2.4%	-12.6%	-10.8%	6.5%

Q4 YTD 2008 over Q4 YTD 2007

	Consolidated	Dental	Medical	International	Technology
Internal Sales Growth	1.3%	4.0%	-7.8%	4.9%	8.7%
Acquisitions	6.2%	0.8%	0.6%	17.9%	16.6%
Local Currency Sales Growth	7.5%	4.8%	-7.2%	22.8%	25.3%
Foreign Currency Exchange	0.8%	0.0%	0.0%	2.7%	-1.5%
Total Sales Growth	8.3% =======	4.8%	-7.2%	25.5%	23.8%

Henry Schein, Inc. 2008 Fourth Quarter and Full Year Reconciliation of GAAP results of continuing operations to non-GAAP results of continuing operations (in thousands, except per share data) (unaudited)

	Fourth 2008	Quarter 2007		Full Y 2008	′ear 2007	% Growth
From Continuing Operations	2000	2007		2000	2001	
Net Sales Operating Income Margin Income from Continuing Operations Diluted EPS from Continuing Operations Net Income Diluted EPS	6.6% \$ 64,208 0.72 56,911 0.64	125,442	-7.5% -16.4% -71 bp -16.3% -13.3% -27.3% -24.7%		387,939 6.6% \$ 236,146 2.59 215,173	8.2% -1 bp 6.3% 6.2% 13.0%
Subtract: Non-GAAP Adjustments Net Sales Operating Income Income from Continuing Operations Diluted EPS from Continuing Operations Net Income Diluted EPS	\$ 23,240 15,991 0.18 15,991 0.18	 		\$ 23,240 19,036 0.21 19,036 0.21	 	
Adjusted Results						
Net Sales Operating Income Margin Income from Continuing Operations Diluted EPS from Continuing Operations Net Income Diluted EPS	\$ 80,199 0,90	125 142	-7.5% 2.1% 76 bp 4.5% 8.4% -6.9% -3.5%	\$6,394,874 442,843 6.9% \$ 270,047 2.96 262,179 2.87	387,939 6.6% \$ 236,146 2.59 215,173	14.2% 35 bp 14.4% 14.3%

Note:

Above reflects adjusted results from continuing operations excluding restructuring costs of \$23,240 (\$15,991 after tax) recorded in the fourth quarter and losses of \$4,511 (\$3,045 after tax) related to the Lehman Brothers bankruptcy recorded in the third quarter. This non-GAAP comparison is being presented in order to provide a more comparable basis for analysis.

CONTACTS: Investors: Steven Paladino Executive Vice President and Chief Financial Officer steven.paladino@henryschein.com (631) 843-5500

> Media: Susan Vassallo Vice President, Corporate Communications susan.vassallo@henryschein.com (631) 843-5562

> > 10 ###